Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are exploring a new multiplex ELISA assay to improve the non-invasive detection of bladder cancer BCa in patients who have microscopic hematuria, a common sign of BCa. This study aims to validate this diagnostic test, which targets a BCa-associated signature in urine samples, to overcome limitations of existing urine-based tests that miss many early or low-grade cancers. Detecting BCa early is crucial since current methods often require invasive bladder examinations. The study involves collecting voided urine samples from patients with microscopic hematuria and analyzing them using the multiplex ELISA assay. The performance of this assay will be compared to standard diagnostic procedures, including cystoscopy, which involves inserting a camera into the bladder, and other urine tests like VUC and NMP-22 BladderChek. This comparison will help confirm the sensitivity and specificity of the new assay within one year. Participants will provide urine samples and undergo cystoscopy and upper tract imaging as part of the hematuria evaluation. Researchers will measure how accurately the multiplex ELISA assay detects bladder cancer compared to current methods. The study includes monitoring for diagnostic performance over a year, with participants expected to complete the full hematuria evaluation during that time. The total duration of participation varies but centers on the one-year outcome assessment.
Actively Recruiting
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are conducting a Phase 3 pediatric clinical trial to study chronic weight management in children and adolescents aged 6 to 17 years who have obesity or are overweight with related health conditions. The study aims to create a master framework that evaluates the safety and effectiveness of medications for these participants. This trial is part of a broader platform trial design with multiple intervention sub-studies ISAs that may start independently as treatments become available. Participants will receive either the study drug orforglipron or a placebo orally, with each intervention sub-study detailing specific treatments. The master protocol sets common entry criteria for all participants across the different sub-studies. Results from the trial will be reported when all intervention sub-studies are completed. During the trial, participants will be monitored from baseline through 72 weeks, with assessments of how many are allocated to each intervention sub-study. Safety and efficacy will be evaluated through ongoing observation and data collection throughout the study period. The trial spans from screening through long-term follow-up, ensuring comprehensive evaluation of the treatments over time.
Actively Recruiting
Researchers are evaluating denecimig Mim8 for adults diagnosed with acquired haemophilia A, a rare bleeding disorder. This Phase 3 open-label study aims to assess the safety and effectiveness of denecimig in reducing bleeding episodes in this population. The study is sponsored by Novo Nordisk AS and will follow participants for up to about one year and five months. Participants will receive subcutaneous injections of denecimig during the study. The treatment period includes a main part lasting 12 weeks followed by an extension phase up to 52 weeks. Denecimig plasma levels and the occurrence of antidrug antibodies will be monitored throughout the treatment. The study also tracks bleeding events and the use of other bleeding management therapies. During the study, participants will be closely monitored for treated and clinically relevant bleeding episodes, infections, and immune responses. The primary outcome is the number of treated bleeds during the first 12 weeks of treatment. Secondary outcomes include bleeding frequency, treatment days with bypassing agents or factor VIII products, and denecimig plasma concentration over one year. Participants are expected to follow study procedures and seek medical attention as needed during the approximately 73-week study period.
Actively Recruiting
Researchers are evaluating treatments for newly diagnosed multiple myeloma in patients who cannot undergo autologous stem cell transplantation. This Phase 3 study compares two drug combinations belantamab mafodotin with lenalidomide and dexamethasone BRd versus daratumumab with lenalidomide and dexamethasone DRd. The goal is to see if BRd extends progression-free survival and improves minimal residual disease negative status compared to DRd. Participants receive either BRd or DRd treatment, continuing until disease progression, death, unacceptable side effects, withdrawal, or study end. Both treatment arms involve the administration of lenalidomide and dexamethasone alongside either belantamab mafodotin or daratumumab. Treatment duration may last up to approximately seven years. During the study, participants will undergo regular assessments including monitoring disease progression, response to treatment, and side effects. Measurements include progression-free survival, overall survival, and the number achieving minimal residual disease negative status. Quality of life questionnaires and blood tests will also be conducted. Safety monitoring includes eye exams and tracking adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.
Actively Recruiting
Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ONO-2020 in treating agitation associated with Alzheimers Disease dementia in patients aged 55 to 90 years in Japan. This phase 2a, multicenter, randomized, double-blind, placebo-controlled study aims to better understand how ONO-2020 affects agitation symptoms in this population. Participants will be randomly assigned to receive either two tablets of ONO-2020 or matching placebo once daily. This treatment will continue for up to 12 weeks, with monitoring of safety and efficacy measures during and up to 16 weeks from the start. The study includes close observation for adverse events and vital signs, as well as laboratory and ECG monitoring. Throughout the trial, participants will undergo assessments including agitation severity using the Cohen-Mansfield Agitation Inventory CMAI, cognitive function tests like the Mini Mental State Exam MMSE, and neuropsychiatric evaluations. Safety will be monitored through vital signs, ECGs, laboratory tests, and the Columbia-Suicide Severity Rating Scale. The total participation period covers up to 16 weeks, including treatment and follow-up assessments.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and pharmacokinetics of orforglipron taken once daily by mouth compared to a placebo in adolescents aged 12 to 17 years who have obesity or are overweight with related health conditions. This Phase 3 randomized, double-blind trial aims to understand how the drug affects body weight and associated health measures over time. Participants who finish the initial study phase can continue receiving orforglipron and lifestyle support for an extended period. Participants are randomly assigned to receive either orforglipron or a placebo orally once daily. The study includes lifestyle interventions focusing on diet and exercise counseling. Those who previously completed the initial study phase and its safety follow-up may join an extension period lasting up to 156 additional weeks to continue treatment and lifestyle support. During the study, participants will be monitored regularly with assessments of body mass index BMI, body weight, waist circumference, blood pressure, cholesterol, glucose, insulin levels, and body fat mass using DXA scans. Quality of life related to weight will also be evaluated. Blood samples will be collected to study the drugs pharmacokinetics. The main outcome is the percent change in BMI from the start to week 72. The total participation time is about 18 months, with ongoing safety monitoring and follow-up.
1-10 of 19
1